Current News

Last week on October 6, 2021, our ZelosDx data was highlighted in a poster presentation given by our Arizona State University collaborator at the 2021 GRAND CHALLENGES IN PARKINSON'S DISEASE Conference. Vladislav Voziyanov, PhD, Graduate Research Assistant at Arizona State University (ASU), presented the poster titled. “Blood Draws to Assess Biomarkers of Inflammation in Peripheral Blood Monocytes in Response to Chronic Implants for Deep Brain Stimulation.” This data in this poster shows that the novel, ZelosDx blood-based assay can detect trace amounts of Glial Fibrillary Acidic in rodent peripheral blood monocytes offering a non-invasive method of measuring inflammation. This work is a part of a collaboration with the laboratory of Dr. Jitendran Muthuswamy at the ASU School of Biological and Health System's Engineering. https://sols.asu.edu/jitendran-muthuswamy

ABOUT GRAND CHALLENGES CONFERENCE- VAN ANDEL INSTITUTE
Grand Challenges in Parkinson’s Disease is an annual scientific symposium that brings together scientists, clinicians, advocates, and people with Parkinson’s to explore the latest innovative Parkinson’s disease research. 

TUCSON, AZ, July 27, 2021 – ZelosDx, Inc. announced today that the company is the recipient of a Small Business Innovation Research (SBIR) Phase l Award from the National Science Foundation (NSF) for a grant entitled, “ Phagocytic Cells in Peripheral Blood as a Novel Diagnostic Tool for Brain Health”.  The company will receive a one-year grant of up to $255,000 to expand the company’s pioneering biomarker research. 

ZelosDx plans to demonstrate that phagocytic cells in peripheral blood present a novel tool for a rapid and low-cost diagnostics of brain health, and to provide such a tool to the clinical research community to enable breakthrough discoveries in disease onset and progression, drug development and patient care. 

In June, our collaborator from Arizona State University, Dr. Jitendran Muthuswamy, presented a poster highlighting our WINDOW INTO THE BRAIN results at the annual North American Neuromodulation Society (NANS) Conference.

As of August 2020, MsDx has re-branded as ZelosDx